Loss of Heterozygosity on Chromosome 10 Is More Extensive in Primary (De Novo) Than in Secondary Glioblastomas

Glioblastomas develop de novo (primary glioblastomas) or through progression from low-grade or anaplastic astrocytoma (secondary glioblastomas). There is increasing evidence that these glioblastoma subtypes develop through different genetic pathways. Primary glioblastomas are characterized by EGFR and MDM2 amplification/overexpression, PTEN mutations, and p16 deletions, whereas secondary glioblastomas frequently contain p53 mutations. Loss of heterozygosity (LOH) on chromosome 10 (LOH#10) is the most frequent genetic alteration in glioblastomas; the involvement of tumor suppressor genes, other than PTEN, has been suggested. We carried out deletion mappings on chromosome 10, using PCR-based microsatellite analysis. LOH#10 was detected at similar frequencies in primary (8/17; 47%) and secondary glioblastomas (7/13; 54%). The majority (88%) of primary glioblastomas with LOH#10 showed LOH at all informative markers, suggesting loss of the entire chromosome 10. In contrast, secondary glioblastomas with LOH#10 showed partial or complete loss of chromosome 10q but no loss of 10p. These results are in accordance with the view that LOH on 10q is a major factor in the evolution of glioblastoma multiform as the common phenotypic end point of both genetic pathways, whereas LOH on 10p is largely restricted to the primary (de novo) glioblastoma.

[1]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[2]  S. Leenstra,et al.  Genetic sub‐types of human malignant astrocytoma correlate with survival , 1998, International journal of cancer.

[3]  M. Wolter,et al.  Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. , 1998, Cancer research.

[4]  P. Kleihues,et al.  p53 and PTEN gene mutations in gemistocytic astrocytomas , 1998, Acta Neuropathologica.

[5]  K. Ichimura,et al.  Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades , 1998, Genes, chromosomes & cancer.

[6]  I. Petersen,et al.  Mapping of multiple DNA gains and losses in primary small cell lung carcinomas by comparative genomic hybridization. , 1994, Cancer research.

[7]  B. Scheithauer,et al.  Histological Typing of Tumours of the Central Nervous System , 1993, World Health Organization.

[8]  P. Kleihues,et al.  Primitive neuroectodermal tumors after prophylactic central nervous system irradiation in children. Association with an activated K‐ras gene , 1992, Cancer.

[9]  Jan Mollenhauer,et al.  DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3–26.1 is deleted in malignant brain tumours , 1997, Nature Genetics.

[10]  R Fankhauser,et al.  Tumours of the nervous system. , 1974, Bulletin of the World Health Organization.

[11]  M Koslow,et al.  Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. , 1994, Journal of neurosurgery.

[12]  Erwin G. Van Meir,et al.  Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas , 1998, Oncogene.

[13]  G. Finocchiaro,et al.  PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas , 1998, Oncogene.

[14]  R. McLendon,et al.  Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. , 1995, Oncogene.

[15]  Mitsuyoshi Nakao,et al.  Identification of a human homolog of the Drosophila neuralized gene within the 10q25.1 malignant astrocytoma deletion region , 1998, Oncogene.

[16]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[17]  Kathleen R. Cho,et al.  Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. , 1997, Cancer research.

[18]  B. Scheithauer,et al.  Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. , 1998, Journal of neurosurgery.

[19]  N. Morton,et al.  A metric map of humans: 23,500 loci in 850 bands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Y. Yonekawa,et al.  Overexpression of the EGF Receptor and p53 Mutations are Mutually Exclusive in the Evolution of Primary and Secondary Glioblastomas , 1996 .

[21]  K. Kinzler,et al.  Characterization of MAD2B and other mitotic spindle checkpoint genes. , 1999, Genomics.

[22]  W. Isaacs,et al.  Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. , 1998, Cancer research.

[23]  G. Finocchiaro,et al.  Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q. , 1996, American journal of human genetics.

[24]  森田 良治 Common regions of deletion on chromosomes 5q, 6q, and 10q in renal cell carcinoma , 1994 .

[25]  W. Cavenee,et al.  Loss of heterozygosity for loci on chromosome 10 is associated with morphologically malignant meningioma progression. , 1993, Cancer research.

[26]  J. Armitage,et al.  Recurrent abnormalities of chromosome bands 10q23–25 in non‐Hodgkin's lymphoma , 1992, Genes, chromosomes & cancer.

[27]  Tiansen Li,et al.  Molecular Characterization of abLIM, a Novel Actin-binding and Double Zinc Finger Protein , 1997, The Journal of cell biology.

[28]  Y. Yonekawa,et al.  PTEN (MMAC1) Mutations Are Frequent in Primary Glioblastomas (de novo) but not in Secondary Glioblastomas , 1998, Journal of neuropathology and experimental neurology.

[29]  Koichiro R. Isshiki,et al.  Chromosome 10 allelic loss in malignant melanoma , 1993, Genes, chromosomes & cancer.

[30]  J. Weissenbach,et al.  Loss of the chromosomal region 10q23-25 in prostate cancer. , 1995, Cancer research.

[31]  N. Moschonas,et al.  Report of the first international workshop on human chromosome 10 mapping 1995. , 1996, Cytogenetics and cell genetics.

[32]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[33]  Arthur R. Brothman,et al.  Mutation of the MXI1 gene in prostate cancer , 1995, Nature Genetics.

[34]  T. Tominaga,et al.  Deletion Mapping of Chromosome 10 in Human Glioma , 1996, Japanese journal of cancer research : Gann.

[35]  ChB PhD MRCPath T. H. Moss MB Tumours of the Nervous System , 1986, Springer London.

[36]  A. Westerveld,et al.  Fine mapping of a region of common deletion on chromosome arm 10p in human glioma , 1997, Genes, chromosomes & cancer.

[37]  R. Kucherlapati,et al.  Report of the Third International Workshop on Human Chromosome 12 Mapping 1995. , 1996, Cytogenetics and cell genetics.

[38]  M. Kurrer,et al.  Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. , 1999, The American journal of pathology.

[39]  P. Kleihues,et al.  Primary and secondary glioblastomas: from concept to clinical diagnosis. , 1999, Neuro-oncology.

[40]  D. Louis,et al.  PTEN mutations in gliomas and glioneuronal tumors , 1998, Oncogene.

[41]  Alec C. Kimmelman,et al.  Loss of heterozygosity of chromosome 10p in human gliomas. , 1996, Genomics.

[42]  Erwin G. Van Meir,et al.  New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26 , 1997, Oncogene.

[43]  R. Wellenreuther,et al.  Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. , 1995, Cancer research.

[44]  B. Scheithauer,et al.  Histological Classification of Tumours of the Central Nervous System , 1993 .

[45]  A. Chishti,et al.  Limatin (LIMAB1), an actin-binding LIM protein, maps to mouse chromosome 19 and human chromosome 10q25, a region frequently deleted in human cancers. , 1997, Genomics.

[46]  I. Petersen,et al.  Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. , 1992, Journal of neurosurgery.

[47]  A. Berchuck,et al.  PTEN/MMAC1 mutations in endometrial cancers. , 1997, Cancer research.

[48]  C. Sommer,et al.  Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization. , 1996, Oncogene.

[49]  W. Cavenee,et al.  Loss of Heterozygosity for 10q22â€"lOqterin Malignant Melanoma Progression' , 1994 .

[50]  Amanda G Paulovich,et al.  When Checkpoints Fail , 1997, Cell.

[51]  J. Cowell,et al.  A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors , 1998, Oncogene.

[52]  J. Olson,et al.  Reliability of Differential PCR for the Detection of EGFR and MDM2 Gene Amplification in DNA Extracted from FFPE Glioma Tissue , 1995, Journal of neuropathology and experimental neurology.

[53]  T. Sekiya,et al.  Structural and functional evidence for the presence of tumor suppressor genes on the short arm of chromosome 10 in human gliomas , 1998, Oncogene.

[54]  D. Louis,et al.  Amplification of the cyclin-dependent kinase 4 (CDK4) gene is associated with high cdk4 protein levels in glioblastoma multiforme , 1996, Acta Neuropathologica.

[55]  Y. Shoshan,et al.  Molecular analysis of two putative tumour suppressor genes, PTEN and DMBT, which have been implicated in glioblastoma multiforme disease progression , 1998, Oncogene.

[56]  S. Tavtigian,et al.  Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXI1 in human glioblastoma multiforme. , 1998, International journal of oncology.

[57]  P. Kleihues,et al.  Genetic profile of gliosarcomas. , 2000, The American journal of pathology.

[58]  J. Herman,et al.  Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. , 1997, Cancer research.

[59]  J. Bruce,et al.  Somatic mutations of PTEN in glioblastoma multiforme. , 1997, Cancer research.